📄 medicine

Castration patterns, PSA suppression, and cardiovascular epidemiology in a nationwide Japanese cohort

This nationwide Japanese cohort study characterizes the unique landscape of castration modalities, PSA suppression levels at treatment initiation, and the rising epidemiology of cardiovascular events among men with prostate cancer from 2010 to 2024, highlighting distinct clinical patterns compared to Western practices.

Original authors: Philippe Pinton

Published 2026-06-28

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Philippe Pinton

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine a massive library in Japan that keeps a record of every medical visit for over 400 hospitals. A researcher named Philippe Pinton went into this library to study a very specific group of people: nearly 86,000 Japanese men diagnosed with prostate cancer.

The goal of this study wasn't to test a new drug or prove that one treatment is "better" than another. Instead, it was like taking a high-resolution snapshot of how doctors in Japan are currently treating these men, what their health looks like at the start of treatment, and how often they run into heart trouble.

Here is the story of the paper, broken down into simple concepts:

1. The Three Ways to Turn Off the "Fuel"

Prostate cancer needs a hormone called testosterone to grow. To stop the cancer, doctors have to cut off this fuel supply. This is called "castration therapy." In Japan, there are three main ways they do this, and they use them differently than doctors in the West:

The Surgical Switch (Surgical Castration): This is the old-school method where the testicles are removed. It's like pulling the plug on a machine. In this study, only a small number of men (637) had this done.
The Chemical Switch (Medical Castration): Instead of surgery, doctors give injections or pills that tell the body to stop making testosterone. This is like turning a dial down. About 19,000 men in the study used this method.
The Super Switch (Deep Castration): This is the most popular method in Japan right now (used by 66,000 men). It combines the chemical switch with a newer, stronger type of medicine (called ARPIs) that blocks the cancer from using any remaining fuel. Think of this as turning the dial down and putting a lock on the fuel tank.

The Twist: Japan also still uses an older drug called flutamide more often than Western countries do. It's like some drivers in Japan still prefer a specific type of older car engine, while the rest of the world has moved on to electric cars.

2. The "Gas Gauge" (PSA Levels)

Doctors use a blood test called PSA to measure how much "fuel" is left for the cancer. It's like a gas gauge on a car.

When the researchers looked at the gas gauges of the men just as they started their treatment, they found something interesting: 62% of them already had a very low reading (below 1.0).
What this means: In Japan, doctors seem to catch the cancer early and start treatment before the "gas tank" gets too full. They are very quick to hit the brakes.

3. The Heart Health Connection

The study also looked at the "engine health" of these men—specifically their hearts.

The Background Noise: Before they even started cancer treatment, a huge number of these men already had heart issues like high blood pressure, high cholesterol, or diabetes. It's like driving a car that already has a few worn-out tires.
The Trend: Over the 15 years the study looked at (2010 to 2024), two things grew steadily:
1. More men were being diagnosed with prostate cancer (the library got bigger).
2. More men were having heart events (like heart attacks or strokes).
The Takeaway: Because men are living longer and getting treated more aggressively, the number of heart problems is rising right alongside the cancer numbers. It's a double burden.

4. What the Paper Does Not Say

It is very important to understand what this paper is not doing:

It is not saying that one type of castration is safer for the heart than another.
It is not proving that the drugs cause heart attacks.
It is not making recommendations on what doctors should do tomorrow.

Instead, it is simply a map. It says, "Here is the landscape of Japan right now. Here is how many people are on the 'Super Switch,' here is how low their PSA levels are, and here is how many heart events are happening."

The Bottom Line

This study is like a detailed weather report for prostate cancer care in Japan. It tells us that:

Japanese doctors are very aggressive about starting treatment early (low PSA levels).
They are using a mix of old and new methods, with the "Super Switch" being the most popular.
The men in this group have a lot of pre-existing heart risks.

The author hopes that by having this clear "weather map," other scientists can use it to build better models in the future to figure out how to keep these men's hearts safe while they fight cancer. But for now, this paper just describes the scene; it doesn't offer the solution yet.

Technical Summary: Castration Patterns, PSA Suppression, and Cardiovascular Epidemiology in a Nationwide Japanese Cohort

Problem Statement
Prostate cancer management involves significant heterogeneity in treatment practices, particularly between Western countries and Japan. In Japan, castration modalities differ substantially, characterized by the persistent use of flutamide, high uptake of Gonadotropin-Releasing Hormone (GnRH) antagonists, and rapid adoption of Androgen Receptor Pathway Inhibitors (ARPIs). While Androgen Deprivation Therapy (ADT) is the cornerstone of systemic treatment, its association with metabolic and cardiovascular morbidity is well-documented. However, there is a lack of large-scale, nationwide real-world data describing precise Prostate-Specific Antigen (PSA) suppression patterns at the exact time of treatment initiation and how these modalities correlate with cardiovascular epidemiology in the Japanese population. Furthermore, serum testosterone monitoring is rare in routine Japanese practice, necessitating the use of PSA dynamics as a pragmatic surrogate for androgen suppression depth.

Methodology
This study is a retrospective, descriptive observational cohort analysis utilizing the Medical Data Vision (MDV) database, one of Japan's largest nationwide claims repositories.

Data Source & Period: Anonymized administrative, diagnostic, procedural, and prescription data from over 400 hospitals spanning January 2010 to December 2024.
Cohort Selection: From an initial pool of 565,348 men diagnosed with prostate cancer (ICD-10 code C61), a rigorous sequential exclusion process was applied. Criteria included a mandatory 12-month baseline period of continuous data capture and the exclusion of patients with pre-existing or prevalent Major Adverse Cardiovascular Events (MACE) during this baseline.
Final Cohort: The study analyzed 85,968 eligible men initiating ADT.
Stratification: Patients were categorized into three mutually exclusive castration modalities:
1. Surgical Castration: Orchiectomy ( $n=637$ ).
2. Medical Castration: LHRH agonists or GnRH antagonists ( $n=19,117$ ).
3. Deep Castration: Conventional ADT combined with an ARPI ( $n=66,000$ ).
  Note: Patients receiving both surgical and medical castration ( $n=214$ ) were retained for descriptive tables but excluded from group-level comparisons.
Analytical Approach: The primary analysis was strictly descriptive, focusing on baseline demographics, PSA categories at initiation, comorbidity profiles, and temporal trends in MACE incidence and prevalence.
- Advanced Analyses: To validate internal consistency and support future research, the study employed Inverse Probability of Treatment Weighting (IPTW) to adjust for selection bias and a Joint Longitudinal-Survival Modeling framework to link time-varying PSA trajectories with MACE risk. These extended analyses are detailed in the Supplementary Material.
Definitions: MACE was defined as acute myocardial infarction, stroke, heart failure, or unstable angina requiring revascularization. PSA suppression depth was contextualized against physiological testosterone thresholds.

Key Results

Cohort Demographics: The mean age at castration initiation was 77.2 years. Cardiovascular comorbidities were prevalent, with hypertension (5.2% active, 32% historical), dyslipidemia, and diabetes common across all groups.
Treatment Modalities: Deep castration (ADT + ARPI) was the predominant modality (66,000 patients), followed by medical castration (19,117) and surgical castration (637).
PSA Suppression: PSA values at initiation were available for 12,811 patients. Notably, 62% of patients presented with PSA levels <1.0 ng/mL, suggesting early initiation of therapy or effective monitoring. The median PSA was lowest in the deep castration group.
Disease Stage: Among the subset with staging data ( $n=5,148$ ), Stage IV disease accounted for 28.3% of cases, with a higher proportion of advanced disease observed in the deep castration group.
Epidemiological Trends (2010–2024):
- Prostate Cancer: Incidence rose from 2,691 cases in 2010 to over 37,000 in 2024. Cumulative prevalence exceeded 365,000 cases.
- Cardiovascular Events: MACE incidence increased from 110 events in 2010 to over 3,200 in 2024. Cumulative MACE prevalence approached 30,000 events.
Statistical Validation: IPTW successfully reduced Standardized Mean Differences (SMDs) below 0.10 across covariates. Joint modeling and sensitivity analyses (including landmark lagged exposure) were used to rule out protopathic bias and confirm the robustness of the cohort's clinical behavior.

Significance and Claims
The paper positions itself as a foundational descriptive study rather than a causal inference trial. Its primary significance lies in:

Characterizing Real-World Practice: It provides a comprehensive, nationwide profile of castration modalities in Japan, highlighting the unique therapeutic landscape where flutamide, GnRH antagonists, and ARPIs coexist.
Biomarker Context: It establishes the distribution of PSA levels at treatment initiation, offering a critical reference for understanding "castration depth" in a setting where testosterone monitoring is uncommon.
Cardio-Oncology Foundation: By documenting the rising burden of both prostate cancer and cardiovascular disease (MACE) in an aging Japanese male population, the study underscores the necessity for integrated cardio-oncology strategies.
Future Research Enabler: The authors explicitly state that these descriptive patterns and the robust epidemiological data serve as a "foundation for future cardio-oncology research." The detailed characterization of PSA trajectories and treatment sequences is intended to support subsequent analytical work, including the application of advanced statistical frameworks like joint modeling to explore biomarker trajectories and clinical outcomes.

The study concludes that while it does not evaluate causal associations, the identified patterns of heterogeneity in castration practices, the central role of PSA monitoring in Japanese clinical decision-making, and the substantial cardiovascular burden provide a necessary framework for optimizing future care and stratifying risk in men undergoing castration therapy.